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Abstract
Background: The transcription factor 7-like 2 (TCF7L2) is a critical component of the Wnt/β-catenin
pathway. Aberrant TCF7L2 expression modifies Wnt signaling and mediates oncogenic effects through the
upregulation of c-MYC and cyclin D. Genetic alterations in TCF7L2 may therefore affect cancer risk. Recently,
TCF7L2  variants, including the microsatellite marker DG10S478 and the nearly perfectly linked SNP
rs12233372, were identified to associate with type 2 diabetes.
Methods: We investigated the effect of the TCF7L2 rs12255372 variant on familial breast cancer (BC) risk
by means of TaqMan allelic discrimination, analyzing BRCA1/2 mutation-negative index patients of 592
German BC families and 735 control individuals.
Results: The T allele of rs12255372 showed an association with borderline significance (OR = 1.19, 95%
C.I. = 1.01-1.42, P = 0.04), and the Cochran-Armitage test for trend revealed an allele dose-dependent
association of rs12255372 with BC risk (Ptrend = 0.04).
Conclusion: Our results suggest a possible influence of TCF7L2 rs12255372 on the risk of familial BC.
Background
The transcription factor 7-like 2 (TCF7L2  alias  TCF-4)
gene product, a HMG box transcription factor, is part of
the Wnt/β-catenin signaling cascade, one of the key mech-
anisms of development and growth regulation in the cell
[1]. Grant et al. [2] have identified TCF7L2 as a novel can-
didate gene for type 2 diabetes and reported an associa-
tion of the microsatellite marker DG10S478 within intron
3. The associated tetranucleotid repeat was shown to have
six alleles, namely alleles 0, 4, 8, 12, 16 and 20. The com-
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bined non-zero alleles of DG10S478 (referred to as X)
were associated with an increased risk in three independ-
ent populations (Danish, Icelandic and US). The compos-
ite at-risk allele X was nearly perfectly correlated with the
T allele of the single nucleotide polymorphism (SNP)
rs12255372, while the G allele was linked to allele 0. Con-
sequently, the rs12255372 T allele showed association
with type 2 diabetes as well [2]. Recent studies have con-
firmed these findings, revealing strong association
between rs12255372 and type 2 diabetes in Dutch and US
cohorts [3,4].
There is accumulating evidence that aberrant activation of
the Wnt/β-catenin pathway has oncogenic effects [5,6].
Wnt signaling results in increased cytosolic levels of β-cat-
enin which is released from the APC/Axin/GSK3β degra-
dation complex and translocated into the nucleus to bind
TCF7L2 [1,2,6]. The transcriptionally competent β-cat-
enin/TCF7L2 complexes provoke an excessive expression
of TCF7L2 target genes, such as the cyclin D and c-MYC
oncogenes, which is a common feature in human cancers,
including breast cancer (BC). This supports the biological
significance and clinical relevance of the Wnt/β-catenin
signaling pathway in carcinogenesis [7-9].
Given these facts, we investigated the effect of the
rs12255372 polymorphism on familial BC risk.
Methods
Study population
We analyzed TCF7L2 rs12255372 in 592 German familial
BC cases and 735 control individuals. The BC cases com-
prised unrelated female index patients (19 to 87 years of
age, median age 45) without mutations in the high-pene-
trance genes BRCA1 and BRCA2. Mutations in the open
reading frame of BRCA1 and BRCA2 were excluded by
applying denaturing high performance liquid chromatog-
raphy (DHPLC) on all exons, followed by direct sequenc-
ing of conspicuous exons. Cases were collected during the
years 1996–2005 through the Institute of Human Genet-
ics (Heidelberg, Germany), the Department of Gynaecol-
ogy and Obstetrics (Cologne, Germany) and the
Department of Medical Genetics (Munich, Germany).
According to the German Consortium for Hereditary
Breast and Ovarian Cancer, BC cases were divided into six
categories based on family history: (A1) families with two
or more breast cancer cases including at least two cases
with onset below the age of 50 years (39.0%); (A2) fami-
lies with at least one male breast cancer case (0.7%); (B)
families with at least one breast cancer and one ovarian
cancer case (18.1%); (C) families with at least two breast
cancer cases including one case diagnosed before the age
of 50 years (25.5%); (D) families with at least two breast
cancer cases diagnosed after the age of 50 years (8.4%)
and (E) single cases of breast cancer diagnosed before the
age of 35 years (8.3%) [10,11]. The TCF7L2 rs12255372
analysis comprised one index case per family. DNA of fur-
ther family members to evaluate segregation of the variant
with BC risk was not available.
The corresponding control series consisted of healthy,
unrelated and ethnically matched blood donors (26 to 68
years of age, median age 49) sharing the ethnic back-
ground with the patients. They were recruited in 2004 and
2005 by the Institute of Transfusion Medicine and Immu-
nology (Mannheim, Germany). The study was approved
by the Ethics Committee of the University of Heidelberg
(Heidelberg, Germany), and written informed consent
was obtained from all individuals.
SNP selection
Grant et al. investigated five SNPs located within a 92.1 kb
linkage disequilibrium (LD) block, encompassing parts of
introns 3 and 4 and the whole of exon 4 [2]. We selected
rs12255372 which was the most highly correlated SNP to
the associated microsatellite marker DG10S478 (r2  =
0.95) for genotyping.
Detection of TCF7L2 rs12255372 genotypes
Genotyping of TCF7L2  rs12255372 was performed by
TaqMan allelic discrimination as described before [12].
Primers and probes were provided by the assay-by-design
service (Applied Biosystems, Foster City, CA). The corre-
sponding sequences are available upon request. Genotyp-
ing errors were excluded by re-genotyping ≥ 10% of the
samples with a concordance rate of 100%.
Statistical analysis
Genotype-specific odds ratios (OR), 95% confidence
intervals (95% C.I.) and P  values were computed by
unconditional logistic regression using the Statistical
Analysis System software (Version 9.1.; SAS Institute Inc.,
Cary, NC). Hardy-Weinberg equilibrium test was under-
taken using Pearson's goodness-of-fit chi-square test with
one degree of freedom. Power calculation was carried out
with the power and sample size software PS [13]. With the
present sample size, we had a power of 80% at a signifi-
cance level of 0.05 to detect an OR of ≥ 1.38.
Results and discussion
The TCF7L2 rs12255372 T allele frequency of the controls
(German Caucasians) was in accordance with those pub-
lished in previous studies (Danish, Dutch, Icelandic and
US Caucasians) [2-4], and the frequencies of rs12255372
genotypes were consistent with Hardy-Weinberg equilib-
rium (P = 0.64, Table 1). The minor T allele of rs12255372
was significantly overrepresented in cases, and we found
an allelic association with an increased familial BC risk
(OR = 1.19, 95% C.I. = 1.01-1.42, P = 0.04, Table 1).
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cannot be excluded. However, according to the Cochran-
Armitage test for trend the association was allele dose-
dependent (Ptrend = 0.04, Table 1), adding consistency to
our data.
The strengths of the present study on BC risk are based on
a large sample size and a homogeneous study cohort of a
single ethnic group. Only BRCA1/2  mutation-negative
familial BC cases were included in order to avoid effects
caused by these high-penetrance susceptibility genes. Our
study comprised individuals selected for familial BC,
since the power of an association study based on cases
with a family history of the disease is considerably higher
compared to a study using unselected cases [14,15].
This is the first study to investigate TCF7L2 as a candidate
gene for cancer susceptibility, suggesting a prominent role
of TCF7L2 variants in human cancers, especially in BC.
According to Duval et al. [16], mutant TCF7L2 stimulates
its transcriptional activity synergistically with APC/β-cat-
enin gene alterations. Moreover, it is predicted to show a
reduced binding of the C-terminal binding protein (CtBP)
which hence loses its capability to repress TCF7L2 activity
[17]. Both hypotheses involve an increase of TCF7L2 tran-
scriptional activation, leading to uncontrolled target gene
expression. Along the lines of Grant et al. [2] who have
ruled out exonic mutations, we assume that the linked
repeat polymorphism DG10S478 is causative itself or that
DG10S478 and rs12255372 are in strong LD with a func-
tional variant affecting transcription, splicing or message
stability.
In summary, our data suggest that TCF7L2 variants may
contribute to the risk of familial BC. Regarding the border-
line significance level of our results, confirmation in an
independent BC cohort is essential. Moreover, it would be
of interest to estimate their impact on further types of
human cancer.
Conclusion
Our data suggest a possible influence of the TCF7L2
rs12255372 variant on the risk of familial BC.
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